Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 4, 2012, Pages 1257-1262

  Madigan, Cressida A ^a   Cheng, Tan Yun ^a   Layre, Emilie ^a   Young, David C ^a   McConnell, Matthew J ^a   Debono, C Anthony ^a   Murry, Jeffrey P ^b   Wei, Jun Rong ^b   Barry III, Clifton E ^c   Rodriguez, G Marcela ^d   Matsunaga, Isamu ^e   Rubin, Eric J ^b   Moody, D Branch ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMYCOBACTIN SIDEROPHORE; IRON; IRON CHELATING AGENT; LIPID; LIPIDOME; MONODEOXYCARBOXYMYCOBACTIN; MONODEOXYMYCOBACTIN; SCAVENGER; SIDEROPHORE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; ENZYME SYNTHESIS; GENE DELETION; GENETIC DATABASE; GENETIC SCREENING; GENETIC VARIABILITY; IRON DEPENDENT REGULATOR; LIPIDOMICS; MASS SPECTROMETRY; MOLECULAR PHYLOGENY; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTIN SYNTHASE B; MYCOBACTIN SYNTHASE G; NONHUMAN; PRIORITY JOURNAL; STARVATION;

BIOSYNTHETIC PATHWAYS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DATABASES, FACTUAL; DNA PRIMERS; IRON; LIPIDS; MASS SPECTROMETRY; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; OXAZOLES; SIDEROPHORES;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84856404106     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1109958109     Document Type: Article

References (28)

1. Schaible UE, Kaufmann SHE (2004) Iron and microbial infection. Nat Rev Microbiol 2: 946-953. (Pubitemid 39562533)
2. Ratledge C (2004) Iron, mycobacteria and tuberculosis. Tuberculosis (Edinb) 84: 110-130.
3. Francis J, MacTurk HM, Madinaveitia J, Snow GA (1953) Mycobactin, a growth factor for Mycobacterium johnei, I: Isolation from Mycobacterium phlei. Biochem J 55: 596-607.
4. Murray MJ, Murray AB, Murray MB, Murray CJ (1978) The adverse effect of iron repletion on the course of certain infections. BMJ 2:1113-1115. (Pubitemid 9043578)
5. Siegrist MS, et al. (2009) Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci USA 106:18792-18797.
6. De Voss JJ, et al. (2000) The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci USA 97:1252-1257. (Pubitemid 30080845)
7. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK (2005) Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 13:29-41. (Pubitemid 40092472)
8. Gobin J, et al. (1995) Iron acquisition by Mycobacterium tuberculosis: Isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA 92: 5189-5193.
9. Quadri LEN, Sello J, Keating TA, Weinreb PH, Walsh CT (1998) Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. Chem Biol 5:631-645. (Pubitemid 28519450)
10. Krithika R, et al. (2006) A genetic locus required for iron acquisition in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103:2069-2074. (Pubitemid 43271624)
11. Rodriguez GM, Voskuil MI, Gold B, Schoolnik GK, Smith I (2002) ideR, An essential gene in Mycobacterium tuberculosis: Role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 70:3371-3381. (Pubitemid 34665972)
12. Cole ST, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. (Pubitemid 28319235)
13. Shi L, et al. (2010) Carbon flux rerouting during Mycobacterium tuberculosis growth arrest. Mol Microbiol 78:1199-1215.
14. Gu S, et al. (2003) Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain. Mol Cell Proteomics 2:1284-1296.
15. Park H-D, et al. (2003) Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 48:833-843. (Pubitemid 36819066)
16. Schnappinger D, et al. (2003) Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 198: 693-704. (Pubitemid 37087769)
17. Matsunaga I, et al. (2004) Mycobacterium tuberculosis pks12 produces a novel polyketide presented by CD1c to T cells. J Exp Med 200:1559-1569. (Pubitemid 40094180)
18. Cox JS, Chen B, McNeil M, Jacobs WR, Jr. (1999) Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402:79-83.
19. Reed MB, et al. (2004) A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87. (Pubitemid 39215112)
20. Barry, CE, 3rd, et al. (1998) Mycolic acids: Structure, biosynthesis and physiological functions. Prog Lipid Res 37:143-179.
21. de Carvalho LPS, et al. (2010) Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem Biol 17:1122-1131.
22. Layre E, et al. (2011) A comparative lipidomics platform for Mycobacterium tuberculosis provides chemotaxonomic analysis for biomarker discovery. Chem Biol 18: 1537-1549.
23. Sartain MJ, Dick DL, Rithner CD, Crick DC, Belisle JT (2011) Lipidomic analyses of Mycobacterium tuberculosis based on accurate mass measurements and the novel Mtb LipidDB. J Lipid Res 52:861-872.
24. Moody DB, et al. (2004) T cell activation by lipopeptide antigens. Science 303:527-531. (Pubitemid 38120851)
25. Chavadi SS, et al. (2011) Mutational and phylogenetic analyses of the mycobacterial mbt gene cluster. J Bacteriol 193:5905-5913.
26. Quadri LEN (2007) Strategic paradigm shifts in the antimicrobial drug discovery process of the 21st century. Infect Disord Drug Targets 7:230-237.
27. Mori K, et al. (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115:610-621. (Pubitemid 40322235)
28. Xu SY, Pauksen K, Venge P (1995) Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest 55:125-131.